Covered recipient · General Payments record
LAURA FERRIS
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$135,900.11
122 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $74,912.19 | 30 |
| Consulting Fee | $50,865.00 | 11 |
| Travel and Lodging | $6,857.30 | 21 |
| Food and Beverage | $3,250.35 | 59 |
| Education | $15.27 | 1 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $34,521.23 | 38 |
| E.R. Squibb & Sons, L.L.C. | $25,802.05 | 19 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $20,096.19 | 14 |
| PFIZER INC. | $15,515.27 | 3 |
| GENZYME CORPORATION | $12,105.90 | 7 |
| Janssen Biotech, Inc. | $7,927.07 | 12 |
| Janssen Research & Development, LLC | $6,250.00 | 1 |
| Regeneron Healthcare Solutions, Inc. | $5,652.06 | 7 |
| Takeda Pharmaceuticals U.S.A., Inc. | $4,099.52 | 3 |
| Amgen Inc. | $2,991.11 | 2 |
| Journey Medical Corporation | $270.31 | 3 |
| Verrica Pharmaceuticals Inc. | $206.76 | 2 |
| Galderma Laboratories, L.P. | $191.86 | 3 |
| Arcutis Biotherapeutics, Inc. | $80.38 | 1 |
| Novartis Pharmaceuticals Corporation | $49.26 | 1 |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $49.24 | 1 |
| UCB, Inc. | $39.02 | 2 |
| Medtronic, Inc. | $23.37 | 1 |
| Lilly USA, LLC | $14.86 | 1 |
| Janssen Scientific Affairs, LLC | $14.65 | 1 |
Page 3 of 3; records 101–122 of 122 matching records. This page contains 22 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
LAURA FERRIS
NPI 1043283229 · CMS profile ID 183114
PITTSBURGH, PA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–122 of 122 matching records. This page contains 22 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1043283229?year=2024&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- LAURA FERRIS, NPI 1043283229, CMS profile ID 183114. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–122 of 122 matching records. This page contains 22 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1043283229?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). LAURA FERRIS, NPI 1043283229, CMS profile ID 183114. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–122 of 122 matching records. This page contains 22 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1043283229?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- LAURA FERRIS, NPI 1043283229, CMS profile ID 183114, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–122 of 122 matching records. This page contains 22 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1043283229?year=2024&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
122 matching records · $135,900.11 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–122 of 122.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Regeneron Healthcare Solutions, Inc. | $31.18 | 02/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114047132 | CMS |
| E.R. Squibb & Sons, L.L.C. | $4,200.00 | 02/08/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101300129 | CMS |
| E.R. Squibb & Sons, L.L.C. | $4,200.00 | 02/08/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101300131 | CMS |
| E.R. Squibb & Sons, L.L.C. | $124.99 | 02/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101300197 | CMS |
| E.R. Squibb & Sons, L.L.C. | $712.12 | 02/08/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101300199 | CMS |
| Lilly USA, LLC | $14.86 | 02/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1135145963 | CMS |
| E.R. Squibb & Sons, L.L.C. | $5,840.00 | 01/30/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101300123 | CMS |
| Amgen Inc. | $2,920.00 | 01/26/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117250519 | CMS |
| E.R. Squibb & Sons, L.L.C. | $134.26 | 01/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101300127 | CMS |
| ABBVIE INC. | $2,025.00 | 01/24/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103150109 | CMS |
| E.R. Squibb & Sons, L.L.C. | $125.82 | 01/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101300125 | CMS |
| GENZYME CORPORATION | $3,343.00 | 01/23/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1140004720 | CMS |
| ABBVIE INC. | $25.31 | 01/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103724656 | CMS |
| Novartis Pharmaceuticals Corporation | $49.26 | 01/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086783421 | CMS |
| Verrica Pharmaceuticals Inc. | $79.65 | 01/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1118380354 | CMS |
| Amgen Inc. | $71.11 | 01/13/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117250521 | CMS |
| ABBVIE INC. | $2,025.00 | 01/10/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103150107 | CMS |
| ABBVIE INC. | $1.58 | 01/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103724652 | CMS |
| ABBVIE INC. | $5.96 | 01/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103724654 | CMS |
| E.R. Squibb & Sons, L.L.C. | $123.66 | 01/10/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101300167 | CMS |
| PFIZER INC. | $15.27 | 01/10/2024 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131910016 | CMS |
| PFIZER INC. | $12,400.00 | 01/02/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131616726 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $1,735.52 | 7 |
| PY2025 | Principal investigator | $147,066.62 | 20 |
| PY2024 | Principal investigator | $350,434.74 | 72 |
| PY2023 | Recipient | $1,749.69 | 9 |
| PY2023 | Principal investigator | $378,357.55 | 136 |
| PY2022 | Recipient | $340.00 | 1 |
| PY2022 | Principal investigator | $495,035.39 | 92 |
| PY2021 | Principal investigator | $555,852.33 | 99 |
| PY2020 | Recipient | $1,966.04 | 2 |
| PY2020 | Principal investigator | $684,617.56 | 107 |
| PY2019 | Recipient | $15,148.85 | 12 |
| PY2019 | Principal investigator | $1,180,310.47 | 100 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
27 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Recipient | Regeneron Pharmaceuticals, Inc. | $506.21 | 12/11/2025 | Covered Recipient Physician | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184117479 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $211.48 | 12/11/2025 | Covered Recipient Physician | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184117481 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $87.12 | 12/11/2025 | Covered Recipient Physician | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184117483 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $30.42 | 12/11/2025 | Covered Recipient Physician | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184117485 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $76.06 | 12/11/2025 | Covered Recipient Physician | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184117487 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $55.31 | 12/11/2025 | Covered Recipient Physician | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184117489 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $7,516.08 | 11/03/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF NORTH CAROLINA HOSP. | TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223272623 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $5,364.00 | 11/03/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF NORTH CAROLINA HOSP. | TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223272625 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $5,313.00 | 11/03/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF NORTH CAROLINA HOSP. | TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223272627 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $768.92 | 10/29/2025 | Covered Recipient Physician | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184117477 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,922.00 | 10/23/2025 | Non-covered Recipient Entity Univ Of Pittsburgh Physicians | A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics | No dispute reported | 06/30/2026 | 1175267680 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $20,000.00 | 09/05/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF NORTH CAROLINA HOSP. | TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223272615 |
| Principal investigator 1 | Janssen Research & Development, LLC | $10,981.60 | 07/31/2025 | Non-covered Recipient Entity Univ Of Pittsburgh Physicians | A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics | No dispute reported | 06/30/2026 | 1175267883 |
| Principal investigator 1 | Arcutis Biotherapeutics, Inc. | $22,465.13 | 07/11/2025 | Non-covered Recipient Entity UPMC Department of Dermatology Clinical Trials | A Phase 1b, Randomized, Vehicle-Controlled, Double-Blind, Pharmacokinetics, Pharmacodynamics, and Safety Study of ARQ-255 Topical Suspension in Healthy Volunteers and Subjects with Alopecia Areata | No dispute reported | 06/30/2026 | 1248163836 |
| Principal investigator 1 | Arcutis Biotherapeutics, Inc. | $2,777.50 | 07/02/2025 | Non-covered Recipient Entity UPMC Department of Dermatology Clinical Trials | A Phase 1b, Randomized, Vehicle-Controlled, Double-Blind, Pharmacokinetics, Pharmacodynamics, and Safety Study of ARQ-255 Topical Suspension in Healthy Volunteers and Subjects with Alopecia Areata | No dispute reported | 06/30/2026 | 1248163832 |
| Principal investigator 1 | Arcutis Biotherapeutics, Inc. | $7,134.33 | 07/02/2025 | Non-covered Recipient Entity UPMC Department of Dermatology Clinical Trials | A Phase 1b, Randomized, Vehicle-Controlled, Double-Blind, Pharmacokinetics, Pharmacodynamics, and Safety Study of ARQ-255 Topical Suspension in Healthy Volunteers and Subjects with Alopecia Areata | No dispute reported | 06/30/2026 | 1248163834 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,490.80 | 05/08/2025 | Non-covered Recipient Entity Univ Of Pittsburgh Physicians | A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics | No dispute reported | 06/30/2026 | 1175267870 |
| Principal investigator 1 | Amgen Inc. | $31,805.00 | 04/24/2025 | Non-covered Recipient Entity UNIVERSITY OF PITTSBURGH MEDICAL CENTER | A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) | No dispute reported | 06/30/2026 | 1246650717 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,411.66 | 04/23/2025 | Non-covered Recipient Entity Univ Of Pittsburgh Physicians | A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics | No dispute reported | 06/30/2026 | 1175267928 |
| Principal investigator 1 | Incyte Corporation | $854.24 | 04/09/2025 | Non-covered Recipient Entity UPMC | An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS) | No dispute reported | 06/30/2026 | 1240609201 |
| Principal investigator 1 | Incyte Corporation | $2,465.00 | 03/24/2025 | Non-covered Recipient Entity UNIVERSITY OF PITTSBURGH MEDICAL CENTER UPMC DERMATOLOGY CLINIC OAKLAND FALK MEDICAL BUILDING | A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis | No dispute reported | 06/30/2026 | 1240608714 |
| Principal investigator 1 | Incyte Corporation | $1,607.50 | 03/24/2025 | Non-covered Recipient Entity UNIVERSITY OF PITTSBURGH MEDICAL CENTER UPMC DERMATOLOGY CLINIC OAKLAND FALK MEDICAL BUILDING | A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis | No dispute reported | 06/30/2026 | 1240608718 |
| Principal investigator 1 | Eli Lilly and Company | $1,230.27 | 03/10/2025 | Non-covered Recipient Entity UNIVERSITY OF PITTSBURGH | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1187892402 |
| Principal investigator 1 | Incyte Corporation | $1,683.90 | 01/27/2025 | Non-covered Recipient Entity UNIVERSITY OF PITTSBURGH MEDICAL CENTER UPMC DERMATOLOGY CLINIC OAKLAND FALK MEDICAL BUILDING | A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis | No dispute reported | 06/30/2026 | 1240608710 |
| Principal investigator 1 | Janssen Research & Development, LLC | $10,676.81 | 01/21/2025 | Non-covered Recipient Entity Univ Of Pittsburgh Physicians Dept Of Neurosurgery | A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics | No dispute reported | 06/30/2026 | 1175267913 |
| Principal investigator 1 | Incyte Corporation | $1,496.80 | 01/06/2025 | Non-covered Recipient Entity UNIVERSITY OF PITTSBURGH MEDICAL CENTER UPMC DERMATOLOGY CLINIC OAKLAND FALK MEDICAL BUILDING | A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis | No dispute reported | 06/30/2026 | 1240608722 |
| Principal investigator 1 | Incyte Corporation | $1,871.00 | 01/06/2025 | Non-covered Recipient Entity UNIVERSITY OF PITTSBURGH MEDICAL CENTER UPMC DERMATOLOGY CLINIC OAKLAND FALK MEDICAL BUILDING | A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis | No dispute reported | 06/30/2026 | 1240608726 |